Bell Potter notes that Neuren has released an update on Acadia's sales and its expected royalties. It said: ...

Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

Despite firming US sales of its Rett syndrome treatment Daybue, Neuren Pharmaceuticals (ASX:NEU) says two-thirds of eligible ...

Shares little changed from Wednesday’s record; ASX hammered on monopoly chatter, costs hit; Domain to exit sharemarket after ...

Dual-listed across the Nasdaq composite and the ASX, Neuren Pharma (ASX:NEU) has jumped +7% down under in the morning Thursday session as sales of its flagship drug DAYBUE jump +14% on Q2 2024. Listen ...

Let's see what awaits Aussie investors during today's session. The post 5 things to watch on the ASX 200 on Tuesday appeared ...

Biotech group Neuren Pharmaceuticals has reported a 14% uptick in quarterly US sales of its Retts syndrome treatment Daybue.

Aug 2025 - Acadia Pharmaceuticals reports a 14% increase in DAYBUE™ net sales, boosting Neuren's royalty income.

With its share price sinking and mistakes piling up, the ASX is facing criticism over governance, accountability and a lack ...